Introduction
============

The significant reduction in morbidity and mortality associated with human immunodeficiency virus (HIV) infection seen with the introduction of highly active antiretroviral therapy has been accompanied by an increase in adverse effects. One of the most common complications is HIV-associated lipodystrophy syndrome, which is observed in 30%--60% of patients treated with nucleoside reverse transcriptase inhibitors and/or protease inhibitors ([@b2-btt-2-917]). This syndrome is characterized by changes in body fat distribution including an increase in centralized fat in the abdomen and cervicodorsal region and a decrease in fat in the face, buttocks, and upper and lower limbs ([@b3-btt-2-917]). Although it is not clear whether peripheral lipoatrophy poses any health risk, central fat accumulation has been associated with increased risk for cardiovascular disease in HIV-infected patients ([@b1-btt-2-917]). These changes in body shape are psychologically disturbing to patients, as they are often perceived as visible indicators of their HIV status ([@b5-btt-2-917]). There is presently no standard therapy to treat HIV-associated lipodystrophy syndrome ([@b13-btt-2-917]).

[@b6-btt-2-917] reported more than a 25% reduction of intra-abdominal fat (IAF) in patients with HIV-associated lipodystrophy treated with ERN. Niacin has long been used in the treatment of dyslipidemias, especially hypertriglyceridemia, and has been considered as a treatment for HIV-associated lipodystrophy. Niacin is thought to inhibit hormone-sensitive lipase (HSL) and enhance lipoprotein lipase (LPL) expression in peripheral fat. Conversely, it inhibits LPL and enhances HSL expression in intra-abdominal fat (IAF) ([@b4-btt-2-917]). HSL is associated with fat mobilization, especially in peripheral adipose tissue, while LPL has been linked to visceral fat storage ([@b12-btt-2-917]). The objective of this study was to identify changes in RNA expression of HSL and LPL in relation to clinical and laboratory results and imaging measurements. Of interest is the RNA expression of HSL and LPL in subcutaneous fat in HIV-infected patients reporting lipodystrophy treated with ERN.

Methods
=======

Patients were recruited from a prospective pilot study examining the safety and tolerability of ERN on HIV-infected individuals with hypertriglyceridemia ([@b14-btt-2-917]). Patients were eligible if they had self-reported body habitus changes confirmed by their physician. Patients had to have received stable potent antiretroviral therapy for at least 12 weeks prior to study entry and during the study. The only exclusion criterion was pregnancy. Informed consent was obtained from all participating patients as per guidelines approved by the Committee on Human Studies of the University of Hawaii, Manoa. Eligible patients were started on ERN at 500 mg once daily at bedtime. The dose of ERN was increased by 500 mg every 4 weeks to a maximum dose of 1500 mg once daily, which was continued for the remainder of the study. Patients underwent limited 8 slice computerized tomography (CT) scans of the abdomen to estimate the amount of IAF content ([@b15-btt-2-917]), dual-energy x-ray absorptiometry (DEXA) scans to determine peripheral fat content, and skin punch biopsies of the mid-thigh to determine RNA expression of HSL and LPL at baseline and after 12 weeks of ERN therapy. The study was completed after 24 weeks of ERN therapy.

A 3-mm skin punch biopsy was performed on the upper lateral thigh at entry and 12 weeks after the initiation of ERN treatment. Follow-up biopsies at the end of the study were obtained adjacent to the initial baseline biopsy. Subcutaneous fat tissue was removed from the rest of the biopsy specimen using a scalpel and forceps and stored in tissue-freezing medium and RNA-Later for nucleic acid extraction at −80 °C. RNA was extracted from the fat tissue using the RNeasy Lipid Tissue Mini Kit for RNA extraction (Qiagen, Valencia, CA, USA) as per the manufacturer's instructions. The quality of the RNA was assessed using UV spectrophotometry and reverse transcriptase PCR (RT-PCR) of the cDNA with β-globin primers.

cDNA was synthesized from the total cellular RNA using the GeneAmp Gold RNA PCR Reagent Kit (Applied Biosystems, Foster City, CA, USA) as per the manufacturer's instructions. PCR with β-globin primers (5'-GAA GAG CCA AGG ACA GGT AC-3' and 5'-CAA CTT CAT CCA CGT TCA CC-3') was performed using the following reaction mix: nuclease free water, 10 × Taq buffer with MgCl~2~, 1.25 dNTP, 10% DMSO, 5' and 3' β-globin primers, and Taq polymerase. 2.0 μL of cDNA was added to the reaction mixture. 1.0 μL of peripheral blood mononuclear cell DNA was used as a positive control and the negative control consisted of the reaction mixture with no added DNA. The reaction conditions were: an initial extension of 94 °C for 5 min, followed by 45 cycles of 94 °C for 1 min, 55 °C for 1 min, 72 °C for 1 min, and a final extension of 72 °C for 3 min in a PE9700 Thermalcycler (Perkin-Elmer, Norwalk, CT, USA). 10.0 μL of each reaction was resolved on a 1.5% agarose/1.0% NuSieve gel.

PCR amplification of the cDNA was performed using HSL primers (5'-CCC ATC ATC TCC ATC GAC TA-3' and 5'-CTT AAC TCC A-3') and LPL primers (5'-TAA TAC GAC TCA CTA ATA GGG-3' and 5'-GTG CCA TAC A-3') ([@b10-btt-2-917]). The reaction mix contained: nuclease free water, 10 × Taq buffer with MgCl~2~, 1.25 dNTP, 10% DMSO, 5' and 3' HSL and LPL primers, and Taq polymerase. The cycling conditions were the same as mentioned above, with the exception of an adjusted annealing temperature of 57 °C for the HSL primers and 52 °C for the LPL primers. PCR products were separated by electrophoresis on a 1.5%/1.0% agarose/NuSieve gel. For the control amplified product (β-globin) and HSL/LPL products, the gels were scanned by a densitometer. The ratio of the measured gene (HSL or LPL) to the β-globin was calculated from the pre- and post-ERN subcutaneous fat tissues to determine the relative changes in HSL and LPL expression.

Results
=======

Four out of 10 patients enrolled in the prospective pilot study reported lipodystrophy and were eligible for this study. The baseline characteristics of the subjects are displayed in [Table 1](#t1-btt-2-917){ref-type="table"}. None of the patients had significant adverse effects and all were able to tolerate 1500 mg of ERN ([@b14-btt-2-917]). Viral load prior to initiating therapy was undetectable in 3 patients and 205 copies/mL in the 4th patient. CD4+ count ranged from 413 to 619 cells/mm^3^ with a mean of 502 cells/mm^3^.

After 12 weeks of ERN therapy, skin biopsies for HSL and LPL were performed. No complications from the skin biopsies were encountered. RT-PCR analysis showed all 8 samples were positive for β-globin. Densitometry readings of the RT-PCR products resulted in pixel densities (light units) for each value (β-globin, HSL, LPL RNA expression). HSL and LPL RNA expression values were then divided by the respective β-globin RNA expressions, which normalized each valued as a ratio. This approach permitted comparisons between individual samples for each patient where each patient was his/her own control. Three of the 4 specimens showed a decrease in normalized HSL expression when comparing pre- and post-ERN treated samples through RT-PCR analysis. An increase in normalized LPL expression was observed in all 4 specimens. Representative samples of HSL and LPL assays are shown in [Figure 1](#f1-btt-2-917){ref-type="fig"}.

After 24 weeks of ERN therapy, all patients showed a decrease in TC and TG levels as seen in [Table 2](#t2-btt-2-917){ref-type="table"}. The mean change in TG level was −385 mg/dL. The mean change in TC level was −34 mg/dL. Three of the 4 patients completed CT and DEXA scans. The changes in IAF of each patient determined by the limited 8 slice abdominal CT scans are shown in [Figure 2](#f2-btt-2-917){ref-type="fig"}. The mean percent change in IAF at the end of the study from baseline was −9.8%. The changes in fat content of both legs of each patient determined by DEXA are also shown in [Figure 2](#f2-btt-2-917){ref-type="fig"}. The mean percent change in leg fat from baseline was −14.0%.

Discussion
==========

By controlling hypertriglyceridemia and moderating HSL and LPL expression, ERN may potentially decrease IAF and increase peripheral fat content. Although the changes in enzyme expression were not quantitated, semi quantitative analysis shows that LPL expression increased after treatment with ERN in all 4 patients, and HSL expression decreased in 3 patients. Only 2 patients demonstrated a loss of IAF and only 1 patient showed an increase in bilateral leg fat. There was no relationship between the change in weight of the patients and the change in either visceral or peripheral adipose tissue content.

A larger sample size and a control group may have produced a clearer effect. In addition, the skin punch biopsies were performed after only 12 weeks of ERN treatment. It is possible that 12 weeks were not sufficient for ERN to exert its full effect on enzyme expression, and therefore on lipolytic activity. This group had a selection bias, as patients self-reported body changes to be eligible to participate in this study, and as a result, may have impacted the results. Some of these individuals may have had mild body habitus changes and the changes from ERN treatment may have been too small to discern. The patients were used as their own controls, which does not allow for examination of the natural progression of lipodystrophy, and compliance was not measured. Furthermore, weight loss due to diet and exercise likely had a considerable impact on adipose changes, which were not controlled for nor quantified in this study.

The results of this pilot study show this method can be used to determine changes in adipose RNA expression of HSL and LPL in HIV-infected individuals treated with ERN. A larger definitive study is needed in the future to validate the use of ERN in HIV-infected individuals suffering from HIV-associated lipodystrophy.
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###### 

Baseline characteristics of HIV-infected individuals with lipodystrophy treated with extended-release niacin

  Patient   Age (yrs)   Gender   Weight (kg)   Triglyceride (mg/dL)   IAF content (kg)   Bilateral leg fat (kg)   CD4 count (cells/mm^3^)   Viral load (copies/mm^3^)   Current ART regimen                           HDL (mg/dL)   Total cholesterol (mg/dL)
  --------- ----------- -------- ------------- ---------------------- ------------------ ------------------------ ------------------------- --------------------------- --------------------------------------------- ------------- ---------------------------
  1         46          M        93.2          1146                   6.5                2.7                      426                       205                         lamivudine, lopinavir/ritonavir, stavudine    34            311
  2         58          M        98.6          300                    8.2                10.3                     413                       \<50                        zidovudine/ lamivudine, nelfinavir mesylate   37            220
  3         43          M        85.5          1264                   2.8                5.8                      619                       \<50                        efavirenz, lopinavir/ritonavir                28            317
  4         47          M        64.0          1189                   NA                 NA                       550                       \<50                        indinavir sulfate, lamivudine, stavudine      26            248

###### 

Changes in weight (kg), triglyceride, IAF, bilateral leg fat, and normalized HSL and LPL expression in HIV-infected individuals treated with extended-release niacin

  Patient   Δ in weight (kg)   Δ in triglyceride (mg/dL)   Δ in total cholesterol (mg/dL)   \% Δ in IAF   \% Δ in bilateral leg fat   Δ in HSL   Δ in LPL
  --------- ------------------ --------------------------- -------------------------------- ------------- --------------------------- ---------- ----------
  1         0.46               --407                       --69                             --10.4        8.4                         --0.06     0.26
  2         --8.18             --118                       --25                             --22.7        --16.3                      --0.14     0.23
  3         1.37               --940                       --21                             3.7           --34.2                      0.08       0.18
  4         --1.36             --76                        --20                             NA            NA                          --0.38     0.82
